Replies to post #799369 on NorthWest Biotherapeutics Inc (NWBO)

[DocLee]

I have no doubt that NICE would prefer to pay for DCVax on a "pay by results basis" rather than pay one large lump sum up front only to see some / many / most patients die (from whatever cause) within a year of payment being made. There are several ways this could be structured and, as a shareholder, I do not find this sort of arrangement basically inimical to the company.

[Baxers]

Yeah Senti, I think you are probably right, however I dont think there is any precedent for this with other autologous cell therapies under NICE. Comparable high cost treatments like Kymriah and Yescarta are single dose or Breyanzi which is double dose, 2 weeks apart (so doesn't really make any odds to NHS cashflow), so the DCVax-L multi-dose treatment schedule is unique in this regard to date (as far as I can find). Therefore I dont see why there couldn't be a new pay-per-dose scheme. Interestingly, all three of the drugs I mentioned above appear to have an outcome linked rebate system whereby some £ is refunded to the NHS by the manufacturer if there is no response within a certain timeframe. Maybe with a pay-per-dose schedule instead of an up-front payment NWBio (by assuming more upfront risk) can forgo any non-response rebate clause.